Alnylam
-
【Product for Licensing】siRNA Therapeutics Targeting AGT for Hypertension
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
-
【Product for Licensing】siRNA Therapeutics Targeting INHBE and another target
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Congratulations to Alnylam and patients who may benefit from this exciting progress!
-
NASH漫谈
“ 上周我们在上海和劲松总闲聊时提及NASH，意犹未尽。正好本周五要参加他们主办的中国NASH大会，所以我们提前把这篇文章发出来，也算给大家暖暖场，热热身。 ” 20…
